NEWS

Lincolnshire Health and Care Selects InterSystems HealthShare to Transform Patient Care for the Region

Clinicians will soon have access to patient's complete medical record for the first time.

Bristol-Myers Squibb and Pfizer Announce Global Real-World Data Program and Present New Analyses of Eliquis (apixaban) at the American College of Cardiology's 65th Annual Scientific

Bristol-Myers Squibb Company and Pfizer Inc. announced today that 17 abstracts will be presented at the American College of Cardiology's 65th Annual Scientific Session, to be held April 2-4 in Chicago, IL.

European Medicines Agency Validates Bristol-Myers Squibb's Application for Opdivo (nivolumab) for the Treatment of Classical Hodgkin Lymphoma Patients

"We are eager to continue to extend the use of Opdivo as a treatment option and potentially provide hematology with its first PD-1 inhibitor,.

PRESS RELEASES

Lilly's Taltz (Ixekizumab) Receives U.S. FDA Approval For The Treatment Of Moderate-To-Severe Plaque Psoriasis

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved Taltz (ixekizumab) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

Phase 3 Study Findings Demonstrate Treatment With Baricitinib Results In Significant Improvements For Patients With Rheumatoid Arthritis Who Had Inadequate Response To Biologics

Eli Lilly and Company and Incyte Corporation announced that detailed results of RA-BEACON - a pivotal phase 3 global study of baricitinib,.

New 2016 ACC/AHA Guideline Focused Update States That It Is Reasonable To Choose Effient (Prasugrel) Over Clopidogrel For Certain ACS-PCI Patients With ST-Elevation Myocardial Infarction And NSTE-ACS

A new guideline focused update provided oral antiplatelet therapy Effient (prasugrel) with a Class IIa recommendation,.